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In 2005, an outbreak of West Nile virus (WNV) disease 
occurred in Sacramento County, California; 163 human cas-
es were reported. In response to WNV surveillance indicat-
ing increased WNV activity, the Sacramento-Yolo Mosquito 
and Vector Control District conducted an emergency aerial 
spray. We determined the economic impact of the outbreak, 
including the vector control event and the medical cost to 
treat WNV disease. WNV disease in Sacramento County 
cost ≈$2.28 million for medical treatment and patients’ pro-
ductivity loss for both West Nile fever and West Nile neuro-
invasive disease. Vector control cost ≈$701,790, including 
spray procedures and overtime hours. The total economic 
impact of WNV was $2.98 million. A cost-beneﬁ  t analysis 
indicated that only 15 cases of West Nile neuroinvasive dis-
ease would need to be prevented to make the emergency 
spray cost-effective.
A
fter its introduction into the eastern United States in 
1999, West Nile virus (WNV) reached California in 
2003 (1). In response, the state enhanced mosquito man-
agement programs to reduce vector populations and virus 
transmission (2). By late summer 2005, WNV disease was 
epidemic in Sacramento County, with more cases reported 
in Sacramento County than in any other county in the na-
tion that year (3). The Sacramento-Yolo Mosquito and Vec-
tor Control District (SYMVCD) responded by conducting 
emergency aerial spraying over the city of Sacramento and 
surrounding areas to reduce mosquito populations.
Effective management of infection rates, illness, and 
death from mosquito-borne pathogens such as WNV re-
quires reduced contact between humans and infected mos-
quitoes (4). No effective treatment exists for WNV; pre-
vention of disease relies on management of mosquitoes 
through various control tactics. Elnaiem et al. (5) and Car-
ney et al. (6) examined the efﬁ  cacy of the 2005 emergency 
aerial spray in Sacramento County, which used pyrethrins 
as the active ingredients to control adult mosquitoes. In 
both studies, an unsprayed area within the county was used 
as the control. Elnaiem et al. showed a total decrease in 
WNV-competent vector mosquitoes, Culex pipiens and Cx. 
tarsalis, of 57.5%, compared with the prespray population 
in the treated area (5). They also observed a decrease in 
WNV infection rates in mosquitoes to 3.9/1,000 for trapped 
females in the treated areas, compared with 6.7/1,000 in the 
untreated areas (5). Carney et al. used illness onset dates 
and residential locations for 152 of the 163 WNV disease 
cases reported in humans in 2005 to determine the efﬁ  cacy 
of the spray event (6). Their results showed no incident hu-
man cases in the treated area after the spray event, com-
pared with 18 cases in the untreated area. Consequently, the 
emergency aerial spray seemed to effectively reduce both 
mosquito populations (5) and human WNV cases (6).
WNV infection can be asymptomatic or symptomatic 
in humans, with a 4:1 ratio (7,8). The disease can be mild, 
resulting in inﬂ  uenza-like symptoms (as in West Nile fever 
[WNF]), or severe, affecting the central nervous system 
symptom (as in West Nile neuroinvasive disease [WNND]) 
(7). Many WNF cases are not reported because they are not 
recognized as WNF; symptoms can resemble a cold or mild 
inﬂ  uenza-like illness, for which medical care is not sought, 
or is underdiagnosed because the additional cost of testing 
would not provide alternative direction to effective pallia-
tive medical care (7,9).
Zohrabian et al. (10) estimated the economic impact 
of the WNV disease outbreak in 2002 in Louisiana, which 
resulted in 24 deaths. They included costs of inpatient and 
outpatient medical care, productivity loss, the state’s public 
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health department, and vector control. Total epidemic costs 
were ≈$20.14 million for the 329 cases, including $9.2 mil-
lion for mosquito control and public health agency costs. 
Zohrabian et al. (11) used the economic data from their 
2004 study to determine the cost-effectiveness of the initia-
tion of a potential WNV vaccination and found that the cost 
of vaccination would not offset the costs in medical care.
Several studies have demonstrated the efﬁ  cacy  of 
mosquito management in response to WNV, but only the 
study by Carney et al. (6) suggested a reduction in human 
WNV cases associated with aerial adult-mosquito control. 
We estimated the economic cost of the 2005 WNV disease 
outbreak in Sacramento County, California, and evaluated 
the reduction in WNV disease necessary to offset the cost 
of emergency vector control. Economic costs for patients’ 
productivity loss and for treatment of disease symptoms, as 
well as for emergency vector control conducted in response 
to the outbreak were also investigated.
Methods
Medical Costs
We estimated costs for the total number of Sacra-
mento County WNV cases in 2005. Different costs were 
associated with WNF and the more severe WNND. The 
Centers for Disease Control and Prevention (CDC) sum-
marizes the reported number of WNV cases for each state, 
including patient’s age, sex, date of onset, case reporting 
date, county of residence, diagnosis (WNF or WNND), 
and outcome (e.g., fatal). According to the CDC database 
for 2005, a total of 935 human WNV cases were report-
ed in California, including 163 cases from Sacramento 
County (3). A total of 117 (71.8%) were diagnosed as 
WNF and 46 (28.2%) as WNND; 1 (0.6%) case was fatal. 
Forty-six (28.2%) patients were >60 years of age, and 2 
(1.2%) were <18 years of age.
For WNND, we calculated costs using similar methods 
as and speciﬁ  c data from Zohrabian et al. (10). Costs of 
inpatient and outpatient care, lost productivity, and miscel-
laneous expenses were summed to estimate the total cost 
of an individual WNND case. Costs for WNF, including 
average price for a physician visit, CDC-approved diagnos-
tic testing, and productivity loss during symptomatic WNV 
disease, were summed to estimate the total cost of an indi-
vidual WNF case.
WNND
We obtained inpatient costs for WNND using the 2005 
hospital patient discharge database from California’s Of-
ﬁ  ce of Statewide Health Planning and Development (OSH-
PD) (J. Teague and J. Morgan, pers. comm.). This database 
included patients with a WNV-related diagnosis who were 
admitted to hospitals within Sacramento County’s ZIP 
codes. It also included average inpatient hospital charge per 
stay and average length of stay for the different WNV diag-
nosis codes (Table 1). Cost data were available for 16 of the 
27 WNND cases reported by Sacramento County hospitals 
in 2005 (some hospitals do not report cost data). Charges 
were averaged for each diagnosis code, and the average 
charge was determined for WNND (no hospital cases were 
reported for WNF). The average charge was then converted 
to the true economic cost by using the average Sacramento 
County hospital cost-to-charge ratio (CCR). Individual 
hospitals’ CCRs were obtained from California’s Depart-
ment of Industrial Regulations (12), and the average was 
based on the number of cases reported at each hospital in 
the county, also obtained from OSHPD. The resulting in-
patient cost was extrapolated to all WNND cases in Sacra-
mento County for the total economic impact.
We estimated outpatient costs for WNND using the 
2002 outpatient costs determined by Zohrabian et al. (10) 
and updated to 2005 using data from the Consumer Price 
Index (CPI) for the western United States, obtained from 
the US Department of Labor, Bureau of Labor Statistics 
(13–15). Zohrabian et al. used hospital cost data reported 
from 119 patients and phone surveys of 139 patients to 
determine related treatment costs for WNV disease symp-
toms. CPI data included the percentage increase for medical 
care services for 2002–2003, 2003–2004, and 2004–2005. 
These increases were applied to the service categories orig-
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Table 1. WNF diagnosis codes and cases, Sacramento County, California, 2005* 
Diagnosis code  Diagnosis
No. hospitalized case-





66.40 WNF, unspecified 0 WNF 0
66.41 WNF with encephalitis  17 Severe (WNND) 14 16 (12–36) 
66.42 WNF with other neurologic 
manifestation
8 Severe (WNND) 2 13 (10–14) 
66.49 WNF with other complications  2 Severe (WNND) 0 21 (13–29) 
WNND totals or averages  27 16 15 (10–36) 
*WNF, West Nile fever; ALOS, average length of stay (J. Teague and J. Morgan, pers. comm.); WNND, West Nile neuroinvasive disease.
†Cases in 2005 obtained from the Patient Discharge Data from California’s Office of Statewide Health Planning and Development (J. Teague and J. 
Morgan, pers. comm.). 
‡Cases that included cost data from the Patient Discharge Database and incorporated into the study. 
§Average length of stay, in days (J. Teague and J. Morgan, pers. comm.). 
¶Not the true ALOS range, determined from data for each diagnosis code. RESEARCH
inated by Zohrabian et al.: hospital treatment, physician 
visits, outpatient physical therapy, occupational therapy, 
and speech therapy. Percentages of total patients for whom 
the service applied were determined by using information 
from Zohrabian et al. for each outpatient category; these 
percentages were then applied to the Sacramento County 
WWND cases for the costs per patient per category.
Miscellaneous costs included nursing home, trans-
portation, home-health aides, and child care costs accrued 
during recovery from WNND. Average nursing home costs 
per day in 2005 were obtained from the Survey of Nursing 
Home and Home Care Costs (16). We calculated the value 
by averaging the national costs for the daily rate of a private 
and semiprivate room in 2005. The total associated costs for 
a nursing home stay was then determined by multiplying 
this value by the average number of days a WNND patient 
spent in a nursing home (96 days) (10). We applied this 
cost to 3.6% of the WNND patients and rounded it to the 
nearest whole number of patients. Transportation, home-
health aides, child care, and other home-help costs were 
calculated by using the cost values determined in Zohra-
bian et al., updated to 2005 by using the CPIs mentioned 
previously (13–15). We applied the resulting transportation 
cost to all WNND cases, and applied costs for home-help 
aides to 14.4% of the 2005 WNND cases and rounded to 
the nearest whole number of patients.
We assumed that productivity loss differentially af-
fected persons in 2 age groups: >60 years and <60 years. 
Productivity loss was also calculated for nonprofessional 
caretakers of WNND patients. We determined the cost for 
a day of work missed by an average Sacramento adult citi-
zen using the mean annual earnings for full-time workers in 
2005 (17). Annual income was divided by 250 work days 
per year. The resulting value was the cost for a day of work 
missed by persons <60 years of age. We calculated the cost 
for a nonwork day missed using Productivity Loss Tables 
from 2000 (18) and updated to 2005 dollars using the US 
Department of Labor, Bureau of Labor Statistics, annual 
earnings (17). The percentage increase from 2000 to 2005 
was applied to the Productivity Loss Tables’ value for a 
nonwork day loss. The resulting value for a nonwork day 
missed also was used for productivity loss for persons >60 
years of age who had WNND. We conservatively assumed 
an average of 50 work days missed (10) and 10 nonwork 
days missed (1 weekend day per week).Thus, total produc-
tivity loss was 60 days. For caretakers of WNND patients, 
productivity loss was assumed to be 25 days, and the as-
sociated cost was the value of a nonwork day missed (10). 
The cost attributed to productivity loss is an estimate; true 
monetary value for pain and distress and the productivity 
loss associated with chronic WNND are uncertain.
WNF
Assumed costs for treating WNF were those of a phy-
sician visit, a diagnostic test, and productivity loss during 
symptomatic WNF. We obtained the average costs for a 
physician visit for a diagnosis or treatment in the western 
United States from 2004 data (19) and updated to 2005, us-
ing the CPI (15) as discussed above.
The CDC-approved diagnostic test for human WNV is 
an immunoglobulin (Ig)M and IgG ELISA for either serum 
or cerebrospinal ﬂ  uid (7). According to CDC, an additional 
test is needed to indicate a false-positive result; however, 
our analysis assumed only costs for the initial diagnostic 
test. We obtained this value by contacting 4 laboratories 
suggested by the California Department of Public Health 
(C. Jean, pers. comm.) (ARUP Laboratories, Salt Lake 
City, UT, USA; Focus Diagnostics Inc., Cypress, CA, USA; 
Quest Diagnostics Inc., Madison, NJ, USA; and Specialty 
Laboratories, Valencia, CA, USA); the costs obtained were 
then averaged. Productivity loss for a missed day of work 
and a missed day of nonwork were calculated by using 
the methods detailed previously. We assumed 5 workdays 
missed because of WNF for persons <60 years of age and 5 
nonwork days missed for persons >60 years of age.
Cost of Mosquito Vector Control
We obtained cost information for the 2005 emergency 
mosquito control aerial spray from SYMVCD. It included 
aerial ultra-low–volume adulticiding over 2 areas in Sac-
ramento County comprising ≈477 km2 (6). Aerial spraying 
was conducted on 6 nights in early and mid-August (5). 
The event costs incorporated overtime hours for SYMVCD 
employees for August 2005. We calculated total overtime 
hours spent on the emergency spray using the difference 
between paid overtime hours for August 2005 and August 
2004. Overtime hours for August 2005 were assumed to 
be additional hours to SYMVCD’s usual vector control 
program, including hours for additional prespray and post-
spray application mosquito trapping, plane preparation 
time, and preparation time for completing the spraying. 
These hours included time spent on other spray events and 
vector control procedures not directly involved in the emer-
gency spray. However, our study incorporated total over-
time hours for August to ensure conservatism. Total cost 
for the emergency spray also included outsource contracts 
(e.g., plane rental, pilot hours) and the insecticide used.
Results
Medical Costs for WNND
A total of 46 WNND cases occurred in Sacramento 
County in 2005. Costs were ≈$33,143 per inpatient and 
≈$6,317 per outpatient for all treatments (Table 2). Cost 
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for each WNND patient estimated to have spent time in 
a nursing home was ≈$18,097. Productivity loss during 
symptomatic WNND cost $10,800 per patient <60 years 
of age and $7,500 per patient >60 years of age (Table 3). 
Total medical costs accrued by all WNND patients was 
≈$2,140,409; total costs for all cases (medical cost plus 
productivity loss) was ≈$2,844,338.
We performed sensitivity analysis for medical treat-
ment of WNND in which we had a range of values using 
10,000 iterations. The hospitals’ CCRs contributed the 
largest amount of variance to the total cost (68.5%), fol-
lowed by the average inpatient cost per WNND patient 
from the 2005 hospital patient discharge database from 
OSHPD (J. Teague and J. Morgan, pers. comm.) (31.4%), 
range $1,910,421–$7,770,354. Results were similar for the 
cost per WNND inpatient (range $13,201–$140,257) and 
the total medical cost for treating WNND.
Medical Costs for WNF
A total of 117 WNF cases were reported for Sacra-
mento County in 2005. Treating each WNF patient cost 
≈$167 for the diagnostic physician visit and ≈$135 for the 
diagnostic test. Productivity loss cost ≈$955 for each pa-
tient <60 years of age and $625 for each patient >60 years 
of age. The total cost for treating reported WNF cases was 
≈$136,839 (Table 4).
Sensitivity analysis for the cost of treating WNF (range 
$132,008–$144,458) showed that the average cost for the 
diagnosis test contributed the largest amount of variance to 
the total cost (84.2%). The cost of a missed day of work for 
patients <60 years of age was 15.8%.
Emergency Vector Control Spray
The emergency spray comprised 1,157 additional 
overtime hours in SYMVCD for August 2005. These 
overtime hours cost ≈$41,790. The emergency spray cost 
≈$660,000 (D. Brown, pers. comm.). Therefore, the emer-
gency aerial spray response to the WNV epidemic cost a 
total of $701,790.
Total Costs and Potential Beneﬁ  ts
Total cost of the 2005 Sacramento County WNV 
epidemic was ≈$2,979,037. Costs for treating WNND pa-
tients alone exceeded costs of emergency vector control by 
$1,438,619, a ratio of 3:1. This difference suggests that for 
the beneﬁ  ts of the vector control to outweigh the cost of the 
epidemic, the spray event would need to prevent only 15 
WNND cases.
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Table 2. Estimated inpatient and outpatient economic costs of WNND cases, Sacramento County, California, 2005* 
Item Cost per case† 
No. cases to 
which cost 
applies‡
% Cases to 
which cost 
applies§
Total cost for 
all cases 
Total cost if 
treatment/service were 
used in all cases 
Inpatient treatment costs  $33,143  46 100 $1,524,570  $1,524,570 
Outpatient costs  Cost per case¶ 
  Outpatient hospital treatment  $333  17 36 $5,668  $15,337 
 Physician  visits  $450  46 100 $20,708  $20,708 
  Outpatient physical therapy  $909  46 100 $41,810  $41,810 
 Occupational  therapy  $4,037  3 7 $12,111  $185,699 
 Speech  therapy  $588  1 1 $588  $27,032 
 Total  $80,885 $290,586 
Nursing home costs  Cost#
  Nursing home stay**  $190 2 4 $36,195 $36,195
 Transportation  $65 46 100 $2,977 $2,977
  Home health aides, babysitters, etc.  $1,569 7 14 $10,983 $505,211
 Total  $50,154 $544,383
Total for all WNND  $2,140,409 $2,844,339 
*WNND, West Nile neuroinvasive disease; BLS, Bureau of Labor Statistics of the US Department of Labor. 
†Estimated by using 2005 data from California’s Office of Statewide Health Planning and Development (J. Teague and J. Morgan, pers. comm.). 
‡WNND cases from the total number of cases reported by the Centers for Disease Control and Prevention (3).
§See (10).
¶Estimated by using data from Zohrabian et al. (10) and updated using data from the US Department of Labor’s Bureau of Labor Statistics (BLS) (13–15).
#Estimated by using data from MetLife Mature Market Institute (16), Zohrabian et al. (10), and BLS (13–15).
**Average length of nursing home stay was 96 days. 
Table 3. Estimated economic costs of WNND cases due to productivity loss, Sacramento County, California, 2005* 
No. patients 
Productivity loss 
Value of work 
day missed† 





days missed  <60 >60 % Cases 
Total costs for 
all cases 
For patients <60 y  $191 $125 50 10 31 100 $334,800
For patients >60 y  $125 60 15 100 $112,500
For caretakers   $125 25 8 4 26 $37,500
Total costs  $484,800
*WNND, West Nile neuroinvasive disease. 
†Estimated by using data from BLS (17).
‡Estimated by using data from Grosse (18) and BLS (17).RESEARCH
Discussion
Since 1999, when WNV was detected in the United 
States, several studies have evaluated the efﬁ  cacy of vector 
control, especially adulticide treatments. Palmisano et al. 
(20) observed an 86% decrease (compared with a 5-year 
average) in WNV-vectoring mosquitoes in 2002 resulting 
from control efforts over a 4-month period in St. Tammany 
Parish, Louisiana. Simpson (21) observed a 64% reduction 
in WNV-carrying mosquito species measured during emer-
gency aerial sprays in 26 Florida counties during 2004 in 
response to hurricanes. Carney et al. (6) and Elnaiem et 
al. (5) provided evidence of the effectiveness of the 2005 
emergency aerial spray as a mosquito control measure in 
Sacramento County by showing a reduction both in mos-
quito populations and WNV disease cases in humans.
Carney et al. (6) documented 18 total WNV disease 
cases outside the spray area after the Sacramento County 
emergency spray and no cases within the spray area, after 
they adjusted for the maximum incubation period of the vi-
rus from infection to onset of symptoms. Of these 18 cases, 
13 were diagnosed as WNF and 5 as WNND. Treating these 
18 patients cost ≈$241,462. However, given the possibility 
of unreported or underdiagnosed WNF cases, the spray 
event may actually have prevented >18 cases (7,9,22,23). 
SYMVCD activities conducted before the emergency pe-
riod most likely prevented some cases.
Estimating the medical costs of WNV patients and the 
true number of cases prevented by the emergency spray are 
uncertain. The estimated dollar amount designated for pro-
ductivity loss from WNV disease was based on the average 
annual salary of a Sacramento County citizen in 2005 and 
an estimated number of work days missed because of the 
disease. This study does not take into account extreme cas-
es of WNND and total number of days a patient is affected 
by the disease. Therefore, the actual cost values associated 
with WNV may be higher.
Our analysis may underestimate the actual cost of the 
WNV outbreak. Pain and distress are difﬁ  cult to estimate 
monetarily but probably are important factors in the com-
prehensive costs of WNV disease. We also did not include 
medical costs associated with non-WNV issues, such as 
mosquito-bite allergenicity or sequelae, which are difﬁ  cult 
to quantify but may be substantial (24). Additionally, we 
did not incorporate the beneﬁ  ts to the human population 
of reducing the nuisance of mosquito bites, irrespective of 
WNV transmission. In Jefferson County, Texas, the ratio of 
the cost of the total household beneﬁ  t to the program cost 
for mosquito abatement was 1.8, according to a county-
wide study on the beneﬁ  t of mosquito control in reducing 
the nuisance of mosquito bites (25). In addition, the actual 
number of persons affected with WNF remains unknown 
because the total number of WNF cases probably was un-
derreported and underdiagnosed (7,9). Busch et al. (26) 
found 353 infections for each reported case of WNND in 
North Dakota from blood screening data in 2003 compared 
with CDC data indicating ≈256 WNV incident infections 
for each WNND case in the United States.
We did not assess human and ecologic risks associ-
ated with the emergency spray. However, previous risk 
assessments that used exposure scenarios for pyrethroids 
and pyrethrins that would exceed those of the Sacramento 
County emergency aerial spray have shown risks substan-
tially below Environmental Protection Agency levels of 
concern (27–34).
The total economic impact of the 2005 WNV disease 
outbreak in Sacramento County was ≈$2.98 million. The 
total cost of medical treatment for the outbreak was $2.28 
million. The actual number of WNV disease cases prevent-
ed by the emergency spray is uncertain. However, the offset 
in cost for the number of cases that may have been prevent-
ed can be compared with the costs of the vector control. If 
only 34 WNF and 14 WNND cases (by using the percent-
ages of each from the diagnoses for Sacramento County in 
2005) were prevented by the spray event, ≈$702,809 would 
have been averted in medical and productivity loss costs, 
thus offsetting the cost of the emergency spray. Also, the 
costs of the emergency spray would have been offset by 
preventing only 15 WNND cases at ≈$706,833.
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Table 4. Estimated economic impact for WNF cases (N = 117), Sacramento County, California, 2005* 
No. patients by age, y
Item Cost <60 >60 Total cost 
Physician visit for diagnosis or treatment in 
the western US, cost per case†
$167 86 31 $19,539
Diagnostic tests, average cost per case‡ $135
Productivity loss Per work day missed§ Per nonwork day missed¶ Total individual cost#
  Value of a lost day $191 $125 $955 $625 $101,505
Total costs for WNF  $136,839
*WNF, West Nile fever; BLS, Bureau of Labor Statistics, US Department of Labor. 
†Estimated by using data from Brown and Beauregard (19) and BLS (15).
‡ELISA immunoglobulin (Ig) G and IgM serum and cerebrospinal fluid. Estimated by using laboratory list prices (ARUP Laboratories, Salt Lake City, UT, 
USA; Focus Diagnostics Inc., Cypress, CA, USA; Quest Diagnostics Inc., Madison, NJ, USA; Specialty Laboratories, Valencia, CA, USA).
§Estimated by using data from BLS (17).
¶Estimated by using data from Grosse (18) and BLS (17).
#Based on 5 workdays missed per person <60 y and 5 nonwork days missed per person >60 y. Cost Analysis of WNV Outbreak
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